# US 2018/0022713 A1 · Heteroaryl compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022713 A1
- Document ID: US20180022713A1
- Status: Published application
- Kind: A1
- Application number: 15/635,954
- Filed: 2017-06-28
- Published: 2018-01-25
- Earliest claimed: 2013-03-15
- Assignees: Celgene CAR LLC; Sanofi
- Applicants: Celgene CAR LLC; Sanofi
- Inventors: Laura Akullian D'Agostino; Robert Tjin Tham Sjin; Deqiang Niu; Joseph John McDonald; Zhendong Zhu; Haibo Liu; Hormoz Mazdiyasni; Russell C. Petter; Juswinder Singh; Matthieu Barrague; Alexandre Gross; Mark Munson
- Web page: https://patentgrep.com/patent/US20180022713A1

## CPC

- C07D 239/80: Oxygen atoms
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/84: Nitrogen atoms
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

## Claims

### Claim 1

A method for inhibiting activity of FGFR4, or a mutant thereof, in a patient or biological sample, comprising the step of administering to said patient or biological sample a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X1 is —NR4, N, —CR4R4 , or —CR4;
X2 is —NR5, N, —CR5R5′, or —CR5;
X3 is N or CR6
X4 is N or CR7;
X5 is N, C, or CH; wherein at least one of X1, X2, X3, X4, or X5 is N;
G is H, O, OR, or N(R)(R);
Ring A is an optionally substituted group selected from a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-10 membered bicyclic saturated, partially unsaturated or aryl ring;
each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 4-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
two R groups on the same nitrogen are taken together with the nitrogen atom to which they are attached to form a 4-7 membered heterocyclic ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 4-7 membered heteroaryl ring having 0-4 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is a warhead group -L-Y; wherein R1 is attached to an atom adjacent to the atom where T is attached, wherein:
R1 is selected from
or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—; or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond and at least one methylene unit of L is replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—; or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one additional methylene unit of L is replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —OC(O)—, or —C(O)O—; or
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—; and
the Y group of R1 is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups; or
L is a covalent bond, —CH2—, —NH—, —C(O)—, —CH2NH—, —NHCH2—, —NHC(O)—, —NHC(O)CH2OC(O)—, —CH2NHC(O)—, —NHSO2—, —NHSO2CH2—, or —SO2NH—, and the Y group of R1 is selected from:
(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or
(ii) C2-6 alkenyl substituted with oxo, halogen, NO2, or CN; or
(iii) C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN; or
(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Re groups; or
(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Re groups; or
(vi)
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or
(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or
(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or
(x)
or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or
(xii)
or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or
(xiv)
or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Re groups; or
(xvi)
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or
L is a covalent bond, —C(O)—, —N(R)C(O)—, or a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain; and the Y group of R1 is selected from:
(i) C1-6 alkyl substituted with oxo, halogen, NO2, or CN; or
(ii) C2-6 alkenyl optionally substituted with oxo, halogen, NO2, or CN; or
(iii) C2-6 alkynyl optionally substituted with oxo, halogen, NO2, or CN; or
(iv) a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 Re groups; or
(v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 Re groups; or
(vi)
or
(vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or
(viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or
(ix) a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 Re groups; or
(x)
or
(xi) a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups; or
(xii)
or
(xiii) a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 Re groups; or
(xiv)
or
(xv) a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 Re groups; or
(xvi)
or
(xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 Re groups;
each Re is independently selected from -Q-Z, oxo, NO2, halogen, CN, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a suitable leaving group selected from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, or diazonium, wherein:
Q is a bivalent C1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, —SO2—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO2—, or —SO2N(R)—; and
each Z is independently hydrogen or C1-6 aliphatic substituted with oxo, halogen, NO2, or CN;
each R2 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R3 is hydrogen, C2-6 alkenyl, —W-Cy, or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, —OR′, or —C(O)O(C1-6 alkyl);
W is absent or is a bivalent C1-3 alkylene chain optionally substituted with one or more R″ and wherein one methylene unit of W is optionally replaced with —O—, —S—, or —NR′—;
each R′ is independently hydrogen or C1-6 alkyl;
each R″ is independently halogen or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from halogen, —CN, oxo, or —OR′;
Cy is phenyl, C3-7 cycloalkyl, or a 3-7 membered monocyclic or 5-10 membered bicyclic saturated, partially unsaturated, or heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Cy is optionally substituted with 1-3 Rx;
each Rx is independently H, —CN, oxo, —NH2, C1-6 alkyl, halogen, —OR′, —N(R′)2, —NHC(O)(C1-6 alkyl), —C(O)N(R′)2, —C(O)O(C1-6 alkyl), —NHSO2(C1-6 alkyl), or —SO2N(R′)2;
or R3 is absent if not allowed by valence;
each of R4 and R4′ is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-8 membered saturated or partially unsaturated carbocyclic ring which is optionally bridged, a 4-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-10 membered bicyclic saturated, partially unsaturated or aryl ring, which is optionally bridged;
each of R5 and R5′ is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
Y is O or NRa;
Ra is hydrogen or an optionally substituted C1-6 aliphatic group;
T is a covalent bond or a bivalent straight or branched, saturated or unsaturated C1-6 hydrocarbon chain wherein one or more methylene units are optionally replaced by —O—, —S—, —N(R)—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)N(R)—, —N(R)C(O)—, —N(R)C(O)N(R)—, —SO2—, —SO2N(R)—, —N(R)SO2—, or —N(R)SO2N(R)—;
q is 0-6; and
each of R6 and R7 is independently —R, halogen, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein Ring A is cyclohexyl, cyclohexenyl, cyclopentyl, cyclobutyl, cyclopropyl, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, piperidine, piperidin-one, pyrrolidine, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene dioxide, or cyclobutene dione.

### Claim 5 (depends on 1)

The method according to claim 1, wherein Ring A is

### Claim at position 5

6-7. (canceled)

### Claim 8 (depends on 5)

The method according to claim 5, wherein each R2 is independently halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2.

### Claim 9 (depends on 5)

The method according to claim 5, wherein each R2 is independently —CH3, —Cl, —F, —CF3, or -OMe; or is selected from

### Claim 10 (depends on 1)

The method according to claim 1, wherein Ring A is selected from:

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 1)

The method according to claim 1, wherein R3 is

### Claim 14 (depends on 1)

The method according to claim 1, wherein R4 is an optionally substituted phenyl.

### Claim 15 (depends on 1)

The method according to claim 1, wherein R4 is an optionally substituted C1-6 aliphatic, or an optionally substituted ring selected from a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 16 (depends on 1)

The method according to claim 1, wherein R4 is ethyl, phenyl, cyclohexyl,

### Claim at position 14

17-18. (canceled)

### Claim 19 (depends on 1)

The method according to claim 1, wherein each of R5 and R5 is independently H, or -Me.

### Claim 20 (depends on 1)

The method according to claim 1, wherein T is a covalent bond.

### Claim 21 (depends on 1)

The method according to claim 1, wherein T is a bivalent straight or branched, saturated or unsaturated C1-6 hydrocarbon chain wherein one or more methylene units are optionally replaced by —O—, —S—, —N(R)—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)N(R)—, —N(R)C(O)—, —N(R)C(O)N(R)—, —N(R)SO2—, or —N(R)SO2N(R)—.

### Claim 22 (depends on 1)

The method of claim 1, wherein the compound is a compound of one of the following formulae:
or a pharmaceutically acceptable salt thereof.

### Claim at position 19

23-28. (canceled)

### Claim 29 (depends on 1)

The method according to claim 1, wherein the compound is a compound of formula I-h:
or a pharmaceutically acceptable salt thereof.

### Claim at position 21

30-33. (canceled)

### Claim 34 (depends on 1)

The method according to claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 1)

The method according to claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable sale thereof.

### Claim 36 (depends on 1)

The method according to claim 1, wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—.

### Claim 37 (depends on 36)

The method according to claim 36, wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—; and
the Y group of R1 is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

### Claim 38 (depends on 37)

The method according to claim 37, wherein L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by —C(O)—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—.

### Claim 39 (depends on 37)

The method according to claim 37, wherein L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by —OC(O)—.

### Claim 40 (depends on 37)

The method according to claim 37, wherein L is —NRC(O)CH═CH—, —NRC(O)CH═CHCH2N(CH3)—, —NRC(O)CH═CHCH2O—, —CH2NRC(O)CH═CH—, —NRSO2CH═CH—, —NRSO2CH═CHCH2—, or —NRC(O)C(═CH2)CH2; wherein the R group of L is H or optionally substituted C1-6 aliphatic; and the Y group of R1 is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

### Claim 41 (depends on 40)

The method according to claim 40, wherein L is —NHC(O)CH═CH—, —NHC(O)CH═CHCH2N(CH3)—, —NHC(O)CH═CHCH2O—, —CH2NHC(O)CH═CH—, —NHSO2CH═CH—, —NHSO2CH═CHCH2—, or —NHC(O)C(═CH2)CH2.

### Claim 42 (depends on 1)

The method according to claim 1, wherein L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond and at least one methylene unit of L is replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—, and one additional methylene unit of L is optionally replaced by cyclopropylene, —O—, —N(R)—, or —C(O)—.

### Claim 43 (depends on 1)

The method according to claim 1, wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the Y group of R1 is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

### Claim 45 (depends on 44)

The method according to claim 44, wherein L is —C≡C—, —NHC(O)C≡CCH2CH2—, —CH2—C≡C—CH2, or CH2OC(═O)C≡C—.

### Claim 46 (depends on 1)

The method according to claim 1, wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one additional methylene unit of L is replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, or —C(O)O—.

### Claim 47 (depends on 1)

The method according to claim 1, wherein:
L is a covalent bond, —C(O)—, —N(R)C(O)—, or a bivalent C1-8 saturated or unsaturated, straight or branched, hydrocarbon chain.

### Claim 48 (depends on 1)

The method according to claim 1, wherein L is a covalent bond, —CH2—, —NH—, —C(O)—, —CH2NH—, —NHCH2—, —NHC(O)—, —NHC(O)CH2OC(O)—, —CH2NHC(O)—, —NHSO2—, —NHSO2CH2—, or —SO2NH—.

### Claim 49 (depends on 48)

The method according to claim 48, wherein L is a covalent bond.

### Claim 50 (depends on 1)

The method according to claim 1, wherein the Y group of R1 is selected from:
wherein each Re is independently selected from halogen.

### Claim 51 (depends on 1)

The method according to claim 1, wherein R1 is selected from:
wherein each Re is independently a suitable leaving group, NO2, CN, or oxo.

### Claim 52

(canceled)

### Claim 53 (depends on 1)

The method of claim 1, wherein R1 is selected from:

### Claim at position 42

54-55. (canceled)

### Claim 56 (depends on 1)

The method according to claim 1, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.

### Claim at position 45

58-68. (canceled)

### Claim 69 (depends on 29)

The method according to claim 29, wherein:
Ring A is an optionally substituted group selected from a 3-8 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is a warhead group -L-Y; wherein R1 is attached to an atom adjacent to the atom where T is attached, wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—; and
the Y group of R1 is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups;
R3 is C1-6 alkyl;
R4 is optionally substituted phenyl; and
Ra is hydrogen.

### Claim 70 (depends on 29)

The method according to claim 29, wherein:
is selected from
R1 is a warhead group -L-Y; wherein:
L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —N(R)SO2—, —SO2N(R)—, —S—, —S(O)—, —SO2—, —OC(O)—, —C(O)O—, cyclopropylene, —O—, —N(R)—, or —C(O)—; and
the Y group of R1 is hydrogen, C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 Re groups;
R3 is C1-6 alkyl;
R4 is optionally substituted phenyl; and
Ra is hydrogen.

### Claim 71 (depends on 69)

The method according to claim 69, wherein L is —NRC(O)CH═CH—, —NRC(O)CH═CHCH2N(CH3)—, —NRC(O)CH═CHCH2O—, —CH2NRC(O)CH═CH—, —NRSO2CH═CH—, —NRSO2CH═CHCH2—, or —NRC(O)C(═CH2)CH2—; wherein the R group of L is H or optionally substituted C1-6 aliphatic; and the Y group of R1 is hydrogen or C1-6 aliphatic optionally substituted with oxo, halogen, NO2, or CN.

### Claim 72 (depends on 69)

The method according to claim 69, wherein R1 is

### Claim 73 (depends on 72)

The method according to claim 72, wherein R4 is selected from:

### Claim 74 (depends on 1)

The method according to claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 75 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 77 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 78 (depends on 1)

The method according to claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 79 (depends on 69)

The method according to claim 69, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 80 (depends on 79)

The method according to claim 79, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.

### Claim 81 (depends on 75)

The method according to claim 75, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 82 (depends on 81)

The method according to claim 81, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.

### Claim 83 (depends on 76)

The method according to claim 76, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 84 (depends on 83)

The method according to claim 83, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.

### Claim 85 (depends on 77)

The method according to claim 77, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 86 (depends on 85)

The method according to claim 85, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.

### Claim 87 (depends on 78)

The method according to claim 78, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly.

### Claim 88 (depends on 87)

The method according to claim 87, wherein the FGFR4 activity, or a mutant thereof, is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.
